


# Immuno-oncology Therapies for the Treatment of **ADVANCED ENDOMETRIAL CANCER:** Which of Your Patients May Benefit from Their Use?

## FACULTY

**Ursula A. Matulonis, M.D.**  
Chief, Division of Gynecologic  
Oncology  
Brock Wilson Family Chair  
Dana-Farber Cancer Institute  
Professor of Medicine  
Harvard Medical School  
Boston, MA

## MEETING INFO

Wednesday, February 2, 2022



# Immuno-oncology Therapies for the Treatment of **ADVANCED ENDOMETRIAL CANCER:** Which of Your Patients May Benefit from Their Use?

## **I. Endometrial Cancer (EC): An Overview**

- a. Epidemiology of endometrial cancer
- b. Molecular classification of endometrial cancer

## **II. Therapeutic Options for the Treatment of Advanced and/or Recurrent EC**

- a. Guideline recommended care for EC
- b. Clinical trial data on the efficacy and safety of:
  - a. Monotherapy with immune checkpoint inhibitors
  - b. Immune checkpoint inhibitors in combination with tyrosine kinase inhibitors
  - c. Other emerging therapies

## **III. Individualizing the Care of Patients with Advanced EC**

- a. Using molecular testing to select treatment options
- b. Managing adverse events
  - a. Recognizing and treating immune-related adverse events
  - b. Strategies to manage treatment-related adverse events
- c. Benefits of multidisciplinary care

## **IV. Interactive case studies**

## **V. Questions and answers**

## **VI. Adjournment**

# Immuno-oncology Therapies for the Treatment of Advanced Endometrial Cancer: Which of Your Patients May Benefit from Their Use?

## FACULTY

### PROGRAM CHAIR

#### **Ursula A. Matulonis, M.D.**

Chief, Division of Gynecologic Oncology  
Brock-Wilson Family Chair  
Dana-Farber Cancer Institute  
Professor of Medicine  
Harvard Medical School  
Boston, MA

## PROGRAM OVERVIEW

This TeleECHO series will explore the management of patients with advanced endometrial cancer through interactive case studies. Faculty will review strategies on personalizing the selection of treatment options based on molecular testing and discuss the management of adverse events with immune-oncology/tyrosine kinase inhibitor combination therapies.

## TARGET AUDIENCE

This activity is intended for U.S.-based gynecologic oncologists, medical oncologists, obstetrician/gynecologists and other healthcare providers involved in the treatment of gynecologic cancers including endometrial cancer.

## LEARNING OBJECTIVES

Upon the completion of this program, attendees should be able to:

- Critique the rationale supporting the biological features of endometrial cancer (EC) that make it an attractive candidate for the use of immuno-oncology (IO) therapies
- Evaluate evidence from clinical trials assessing available and emerging therapies for the treatment of patients with advanced EC
- Devise strategies to manage the immune-related adverse events (irAEs) and treatment-related adverse events (trAEs) associated IO/tyrosine kinase inhibitor (TKI) combination therapies in development for patients with advanced EC
- Support multidisciplinary care teams for the management of patients with EC

## ACCREDITATION STATEMENT

Med Learning Group is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

This CME activity was planned and produced in accordance with the ACCME Essentials.

## CREDIT DESIGNATION STATEMENT

Med Learning Group designates this live virtual activity for a maximum of 1.0 *AMA Category 1 Credit*<sup>™</sup>.

Physicians should claim only the credit commensurate with the extent of their participation in the live virtual activity.

## **NURSING CREDIT INFORMATION**

Purpose: This program would be beneficial for nurses involved in the care of patients with advanced endometrial cancer.

**CNE Credits:** 1.0 ANCC Contact Hour.

## **CNE ACCREDITATION STATEMENT**

Ultimate Medical Academy/CCM is accredited as a provider of nursing continuing professional education development by the American Nurses Credentialing Center's Commission on Accreditation.

Awarded 1.0 contact hour of continuing nursing education of RNs and APNs.

## **DISCLOSURE POLICY STATEMENT**

In accordance with the Accreditation Council for Continuing Medical Education (ACCME) Standards for Commercial Support, educational programs sponsored by Med Learning Group must demonstrate balance, independence, objectivity, and scientific rigor. All faculty, authors, editors, staff, and planning committee members participating in an MLG-sponsored activity are required to disclose any relevant financial interest or other relationship with the manufacturer(s) of any commercial product(s) and/or provider(s) of commercial services that are discussed in an educational activity.

## **DISCLOSURE OF CONFLICTS OF INTEREST**

| <b>Faculty Member</b>            | <b>Disclosures</b>   |
|----------------------------------|--|
| <b>Ursula A. Matulonis, M.D.</b> | She has been a consultant for Astrazeneca, Merck, Novartis, Trillium, and Blueprint Med. She has also worked with DSMB for Symphogen, Alkermes, GSK, NextCure, Agenus and Imvax. |

## **CME Content Review**

The content of this activity was independently peer reviewed.

The reviewer of this activity has nothing to disclose.

## **CNE Content Review**

The content of this activity was peer reviewed by a nurse reviewer.

Douglas Cox, MSN, MHA, RN

Ultimate Medical Academy/CCM – Lead Nurse Planner

The reviewer of this activity has nothing to disclose

## **Staff Planners and Managers**

The staff, planners, and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME/CE activity:

Matthew Frese, MBA, General Manager of Med Learning Group, has nothing to disclose.

Christina Gallo, SVP, Educational Development for Med Learning Group, has nothing to disclose.

Diana Tommasi, PharmD, Medical Director for Med Learning Group, has nothing to disclose.

Lauren Welch, MA, VP, Accreditation and Outcomes for Med Learning Group, has nothing to disclose.

Lisa Crenshaw, Senior Program Manager for Med Learning Group, has nothing to disclose.

Russie Allen, Accreditation and Outcomes Coordinator for Med Learning Group, has nothing to disclose.

Morgan Kravarik, Associate Program Manager for Med Learning Group, has nothing to disclose.

Douglas Cox, MSN, MHA, RN, UMA/CCM – LNP, has nothing to disclose.

### **DISCLOSURE OF UNLABELED USE**

Med Learning Group requires that faculty participating in any CME activity disclose to the audience when discussing any unlabeled or investigational use of any commercial product or device not yet approved for use in the United States.

During this lecture, the faculty may mention the use of medications for both FDA-approved and non-approved indications.

### **METHOD OF PARTICIPATION**

There are no fees for participating and receiving CME credit for this live virtual activity. To receive CME/CNE credit participants must:

1. Read the CME/CNE information and faculty disclosures.
2. Participate in the web-based live activity.
3. Submit the evaluation form to Med Learning Group.

You will receive your certificate upon completion.

### **DISCLAIMER**

Med Learning Group makes every effort to develop CME activities that are science based.

This activity is designed for educational purposes. Participants have a responsibility to use this information to enhance their professional development in an effort to improve patient outcomes. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information. The participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision making before applying any information, whether provided here or by others, for any professional use.

For CME questions, please contact Med Learning Group at [info@medlearninggroup.com](mailto:info@medlearninggroup.com)

Contact this CME provider at Med Learning Group for privacy and confidentiality policy statement information at <http://medlearninggroup.com/privacy-policy/>



Provided by Med Learning Group



This activity is co-provided by Ultimate Medical Academy/Complete Conference Management (CCM).

This activity is supported by an independent medical education grant from Eisai, and Merck & Co., Inc.

Copyright © 2022 Med Learning Group. All rights reserved. These materials may be used for personal use only. Any rebroadcast, distribution, or reuse of this presentation or any part of it in any form for other than personal use without the express written permission of Med Learning Group is prohibited.

# *Immuno-Oncology Therapies for the Treatment of Advanced Endometrial Cancer: Which of Your Patients May Benefit from Their Use?*

**Ursula Matulonis, MD**

Chief, Division of Gynecologic Oncology  
Brock Wilson Family Chair  
Dana-Farber Cancer Institute  
Professor of Medicine  
Harvard Medical School  
Boston, MA

1

## **Disclosures**

- **Dr. Matulonis** has been a consultant for AstraZeneca, Merck, Novartis, GSK, Trillium, Agenus, and Blueprint Med. She serves on a scientific advisory board for NextCure, Rivkin Foundation, Ovarian Cancer Research Alliance and DSMB: Symphogen, Alkermes, Advaxis.
- During this lecture, faculty may mention the use of medications for both US Food and Drug Administration (FDA)-approved and non-FDA-approved indications
- This educational activity is supported by an independent medical education grant from Eisai and Merck & Co., Inc.

2

## Learning Objectives

- Critique the rationale supporting the biological features of endometrial cancer (EC) that make it an attractive candidate for the use of immuno-oncology (IO) therapies
- Evaluate evidence from clinical trials assessing available and emerging therapies for the treatment of patients with advanced EC
- Devise strategies to manage the immune-related adverse events (irAEs) and treatment-related adverse events (trAEs) associated with IO/tyrosine kinase inhibitor (TKI) combination therapies in development for patients with advanced EC
- Support multidisciplinary care teams for the management of patients with EC

3

## Endometrial Cancer (EC)

- 65,950 new cases per year with 793,846 women living with uterine cancer in the US
- Incidence and death rates are increasing in the US
  - ~1% increase in incidence per year (driven by non-endometrioid subtypes) AND death rates have been rising by ~1.9% per year
- 12,550 women will die of EC per year (2022 estimate)
- Black women are diagnosed at later stages than White women and have poorer 5-year survival rates


### FDA-approved drugs for EC



US = United States; MSI-H = microsatellite instability-high; MSS = microsatellite stable; MMR = mismatch repair; Pembro = pembrolizumab; TMB = tumor mutational burden. Siegel RL, et al. *CA Cancer J Clin.* 2022;72:7-33. Clarke MA, et al. *J Clin Oncol.* 2019;37:1895-1908. McAlpine JN, et al. *Cancer.* 2016;122:2787-2798. Lortet-Tieulent J, et al. *J Natl Cancer Inst.* 2018;110:354-361. Oaknin A, et al. *JAMA Onc.* 2020. Makker V, et al. Society of Gynecologic Oncology (SGO) 2021; Abstract 0008/#785. Cancer Today. Cancer fact sheets: corpus uteri. 2018. (<https://gco.iarc.fr/today/fact-sheets-cancers>).

4

## EC Cancer Statistics in the US and Globally in 2020



Sung H, et al. *CA Cancer J Clin.* 2021;71:209-249. Siegel RL, et al. *CA Cancer J Clin.* 2020;70:7-33.



5

## Molecular Classification of EC

TCGA molecularly classified EC into 4 groups

- *POLE* (DNA polymerase  $\epsilon$  catalytic subunit) ultramutated
- Microsatellite instability (MSI) hypermutated
- Copy number low
- Copy number high (serous)

TCGA



CN = copy number; TCGA = The Cancer Genome Atlas.  
Levine DA, et al. *Nature.* 2013;497:67-73.

6



## GOG 209: Study Design

### Carboplatin and Paclitaxel for Advanced EC

- Established carboplatin and paclitaxel as the standard of care chemotherapy for patients with advanced stage or recurrent cancer

- Stage III, stage IV, or recurrent endometrial carcinoma
- No prior cytotoxic chemotherapy
- Estrogen and progesterone receptor assessed on primary tumor
- Known LVEF <50% within 6 months of study entry ineligible
- N = 1381

R

Paclitaxel-carboplatin cycles 1 to 7  
 Carboplatin AUC 6 IV on Day 1  
 Paclitaxel 3-hour 175 mg/m<sup>2</sup> on Day 1

TAP cycles 1 to 7  
 Doxorubicin 45 mg/m<sup>2</sup> IV on Day 1  
 Cisplatin 50 mg/m<sup>2</sup> on Day 1  
 Paclitaxel 3-hour 160 mg/m<sup>2</sup> on Day 2  
 Filgrastim 5 mcg/kg on Days 3-12 or  
 pegfilgrastim 6 mg on Day 3

AUC = area under the curve; GOG = Gynecologic Oncology Group; LVEF = left ventricular ejection fraction; R = randomized; TAP = paclitaxel/doxorubicin/cisplatin.  
 Miller DS, et al. *J Clin Oncol.* 2020;38:3841-3850.


7

## GOG 209: Efficacy Summary


### Carboplatin and Paclitaxel for Advanced EC

- Established carboplatin and paclitaxel as standard of care for patients with advanced stage or recurrent disease

Progression-free survival



Overall survival



Carbo = carboplatin; Pac = paclitaxel

Miller DS, et al. *J Clin Oncol.* 2020;38:3841-3850.

8

## Systemic Therapies for Recurrent/Newly Diagnosed Advanced EC

- **Standard of care: carboplatin and paclitaxel (GOG 209, GOG 261)**
  - Addition of trastuzumab in HER2+ uterine serous cancers in newly diagnosed advanced cancer: PFS and OS improvements in newly diagnosed patients
- **Beyond carboplatin/paclitaxel**
  - Pembrolizumab (mismatch repair [MMR] deficient or MSI-high tumors) (FDA-approved)
  - Pembrolizumab and lenvatinib (MMR proficient recurrent EC after standard therapies) (FDA-approved)
  - Hormonal therapy: progestins (11-55% ORR), megestrol/tamoxifen (33% ORR), aromatase inhibitors (~9% ORR)
  - Antiangiogenic agents/other TKIs: bevacizumab (13.5% ORR), cabozantinib (14% ORR)
  - Alternative chemotherapies and other targeted agents
    - Liposomal doxorubicin (9% ORR), paclitaxel (25% ORR), topotecan (9% ORR)
    - Combination letrozole and everolimus (24-32% response rate): *CTNNB1* mutation predictive of response; serous histology not predictive of response
    - WEE1 inhibitors
    - Cyclin-dependent kinases 4 and 6 (CDK4/6) inhibitors
    - ATR inhibitors
    - Anti-HER2 antibody drug conjugates

ATR = ataxia telangiectasia and RAD3 related; HER2 = human epidermal growth factor receptor 2; ORR = objective response rate; OS = overall survival; PFS = progression-free survival  
 Miller D, et al. *Gyn Oncol*. 2012;125(3):771-773. FDA package inserts. Lentz SS, et al. *J Clin Oncol*. 1996;14(2):357-361. Aghajanian C, et al. *J Clin Oncol*. 2011;29:2259-2265. Thigpen JT, et al. *J Clin Oncol*. 1999;17(6):1736-1744. Fiorica JV, et al. *Gyn Oncol*. 2004;92(1):10-14. Whitney CW, et al. *Gyn Oncol*. 2004;92(1):4-9. Dhani S, et al. *Cancer Clin Res*. 2020;26(11):2477-2486. Bogliolo S, et al. *Arch Gyn Oncol*. 2016;293(4):701-708. Slomovitz BM, et al. *J Clin Oncol*. 2015;33(8):930-936. Slomovitz BM, et al. SGO 2018; Abstract 1. Miller et al, 2002 GOG 261: Powell et al, JCO 2022

9

## National Comprehensive Cancer Network® (NCCN) Guidelines

Primary or adjuvant treatment when used for uterine-confined high-risk disease

Preferred regimens: Carboplatin/paclitaxel

### Recurrent or metastatic disease

|  | Preferred regimens  | Other recommended regimens  |
|--|---|---|
| <b>Systemic therapies</b>  | <ul style="list-style-type: none"> <li>• Carboplatin/paclitaxel (category 1 for carcinosarcoma)</li> <li>• Carboplatin/paclitaxel/trastuzumab (for stage III/IV or recurrent HER2-positive uterine serous carcinoma)</li> </ul>           | <ul style="list-style-type: none"> <li>• Carboplatin/docetaxel</li> <li>• Cisplatin/doxorubicin</li> <li>• Cisplatin/doxorubicin/paclitaxel</li> <li>• Carboplatin/paclitaxel/bevacizumab</li> <li>• Cisplatin</li> <li>• Carboplatin</li> <li>• Doxorubicin</li> <li>• Liposomal doxorubicin</li> <li>• Paclitaxel</li> <li>• Albumin-bound paclitaxel</li> <li>• Topotecan</li> <li>• Bevacizumab</li> <li>• Temsirolimus</li> <li>• Docetaxel (category 2B)</li> <li>• Ifosfamide (for carcinosarcoma)</li> <li>• Ifosfamide/paclitaxel (for carcinosarcoma)</li> <li>• Cisplatin/ifosfamide (for carcinosarcoma)</li> </ul> |
| <b>Biomarker-directed systemic therapy for second-line treatment</b> | <ul style="list-style-type: none"> <li>• Lenvatinib/pembrolizumab (category 1) for non-MSI-high [MSI-H]/non-MMR-deficient [dMMR] tumors</li> <li>• Pembrolizumab for tumor mutational burden-high (TMB-H) or MSI-H/dMMR tumors</li> </ul> | <ul style="list-style-type: none"> <li>• Nivolumab for dMMR/MSI-H tumors</li> <li>• Dostarlimab-gxly for dMMR/MSI-H tumors</li> <li>• Larotrectinib or entrectinib for neurotrophic tyrosine receptor kinase (NTRK) gene fusion-positive tumors (category 2B)</li> <li>• Avelumab for dMMR/MSI-H tumors</li> <li>• Cabozantinib</li> </ul>  |

NCCN guidelines for uterine neoplasms v1 2022 (<https://www.nccn.org/guidelines/guidelines-detail?category=1&id=1473>).

10

# NCCN Guidelines

## Hormone therapy


| Preferred regimens   | Other recommended regimens  | Useful in certain circumstances                         |
|--|---|---|
| <ul style="list-style-type: none"> <li>• Medroxyprogesterone acetate/tamoxifen (alternating)</li> <li>• Megestrol acetate/tamoxifen (alternating)</li> <li>• Progestational agents                             <ul style="list-style-type: none"> <li>▶ Medroxyprogesterone acetate</li> <li>▶ Megestrol acetate</li> <li>▶ Levonorgestrel intrauterine device (IUD) (for select fertility-sparing cases)</li> </ul> </li> <li>• Aromatase inhibitors</li> <li>• Tamoxifen</li> <li>• Fulvestrant</li> </ul> | <ul style="list-style-type: none"> <li>• Everolimus/letrozole (for endometrioid histology)</li> </ul> | <ul style="list-style-type: none"> <li>• N/A</li> </ul> |

NCCN guidelines for uterine neoplasms v1 2022 (<https://www.nccn.org/guidelines/guidelines-detail?category=1&id=1473>).

11

## Benefit of Adding Trastuzumab in HER2+ Uterine Serous Carcinoma at Diagnosis with Carboplatin/Paclitaxel

- ~25% to 30% of patients with uterine serous carcinoma have HER2 amplification<sup>1</sup>
- Single agent trastuzumab in advanced/recurrent HER2+ uterine cancer has limited activity<sup>2</sup>
- Randomized phase 2 study of carboplatin/paclitaxel/trastuzumab vs carboplatin/paclitaxel showed increased PFS in HER2+ uterine serous cancer<sup>3</sup>
  - 58 evaluable patients (41 advanced, 17 recurrent) ; eligibility included 3+ IHC for HER2 or 2+ IHC plus FISH+





1. Levine DA, et al. *Nature*. 2013;497:67-73. 2. Fleming GF, et al. *Gyn Oncol*. 2010;116(1):15-20. 3. Fader AN, et al. *J Clin Oncol*. 2018;36(20):2044-2051.

12

## Trastuzumab in HER2+ Uterine Serous Carcinoma with Carboplatin/Paclitaxel

- OS benefit observed in women with newly diagnosed stage III or IV serous cancer
- No OS benefit using trastuzumab in recurrent serous cancer



Fader AN, et al. *Clin Cancer Res.* 2020;26:3928-3935.

13

## Other HER2 Targeted Agents; DS8201a

- DS8201A: anti-HER2 antibody, tetrapeptide-based linker, and cytotoxic topoisomerase I inhibitor
- Examples of ongoing studies that allow recurrent endometrial cancer:
  - DS8201a + olaparib (NCT04585958) (focused on serous histology)
  - DESTINY-PanTumor02: Basket study, HER2+, multiple gynecologic cancers eligible (NCT04482309)
  - DS8201a + ceralasertib (AZD6738) (NCT04704661), phase 1
  - ESMO 2021: single agent DS8201A in HER2+ uterine carcinosarcomas, + results (below)


### Key inclusion criteria

- Unresectable uterine carcinosarcoma histologically confirmed by the pathologist of each trial site
- Progression after 1 or more lines of prior chemotherapy
- HER2-positive (IHC score 1+ or higher) by central pathological review
- HER2 low = 1+ and HER2 high = 2 or 3+
- Age ≥20 years
- Performance status (ECOG) 0 or 1
- ≥1 measurable disease (RECIST version 1.1)

### Key exclusion criteria

- Active concurrent malignancy (except for carcinoma in situ)
- History of interstitial lung disease
- Symptomatic congestive heart failure (New York Heart Association Classification II-IV)
- Cancerous meningitis/symptomatic brain metastasis/spinal metastasis requiring surgery

### Efficacy (central review)



| Confirmed Response rate | CR (n, %) | PR (n, %) | SD (n, %) | PD (n, %) | ORR (%) |
|-------------------------|-----------|-----------|-----------|-----------|---------|
| HER2-high (n=22)        | 1 (4.5)   | 11 (50)   | 10 (45.5) | 0 (0)     | 54.5    |
| HER2-low (n=10)         | 0 (0)     | 7 (70)    | 3 (30)    | 0 (0)     | 70      |

14

## Current FDA Approvals for EC Based on MS Status

Patients with MSI-high, dMMR deficient, or TMB-high cancer

Pembrolizumab

Patients with MSS or MMR proficient cancers

Lenvatinib/Pembrolizumab

Patients with dMMR recurrent or advanced EC

Dostarlimab (accelerated FDA approval)

Lenvima (Lenvatinib®) PI 2021 (<https://www.lenvima.com/-/media/Project/EISA/Lenvima/PDF/prescribing-information.pdf>). Dostarlimab (Jemperli) PI 2021 ([https://www.accessdata.fda.gov/drugsatfda\\_docs/label/2021/761174s000lbl.pdf](https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/761174s000lbl.pdf)).

15

## Microsatellites

- Microsatellites are repetitive DNA sequences that are distributed across the genome
- DNA mismatch repair is a process used to restore DNA integrity after mismatch errors occur
  - 4 genes that play a critical role are *MLH1*, *MSH2*, *MSH6*, and *PMS2*
- Microsatellite instability is a condition of genetic hypermutation resulting from defective DNA mismatch repair

Luchini C, et al. *Ann Oncol*. 2019;30:1232-1243.

16

## Molecular Testing and Mismatch Repair Assessment

- The presence of MMR deficiency, or MSI, is detected clinically by
  - 1) MMR protein immunohistochemistry (IHC) to detect loss of MMR protein expression (usually for 4 proteins: *MLH1*, *PMS2*, *MSH2*, and *MSH6*)
  - 2) Polymerase chain reaction (PCR) at a panel of microsatellite loci in the genome to detect repetitions
  - 3) Observation of an MMR mutational signature in next generation sequencing tests
- NCCN guidelines recommend universal testing of ECs for MMR proteins/MSI
- Testing can be done on initial endometrial biopsy or the final hysterectomy specimen
- *MLH1* loss should be further evaluated for promoter methylation to assess for an epigenetic process
- 30% of ECs are MMR deficient at diagnosis

NCCN guidelines for uterine neoplasms v1 2022 (<https://www.nccn.org/guidelines/guidelines-detail?category=1&id=1473>). Bonneville R, et al. *JCO Precis Oncol.* 2017;1-15.

17

## Single Agent Immune Checkpoint for Recurrent MMR Deficient (MSI-high) EC

- Pembrolizumab was FDA-approved in 2017 for any solid tumor that is MMR deficient or MSI-high
- Dostarlimab was FDA-approved in 2021 for MSI-high recurrent EC
- Up to 30% of ECs are dMMR/MSI-high

|               | Number of patients with EC (MMR deficient) | Response rate (RR) | Duration of response range |
|---------------|--|--------------------|----------------------------|
| Pembrolizumab | 49   | 57.1%              | 2.9 to 27+ months          |
| Avelumab      | 15   | 27%                | Not reported               |
| Dostarlimab   | 104  | 42.3%              | Not reached                |
| Durvalumab    | 35   | 40%                | Not reported               |


**Response rates are much lower in MMR proficient cancers; not FDA-approved for microsatellite stable (MSS) tumors.**

Marabelle A, et al. *J Clin Oncol.* 2020;38:1-10. Antill YC, et al. American Society of Clinical Oncology (ASCO) 2019; Abstract 5501. Pembrolizumab (Keytruda®) PI 2021 ([https://www.merck.com/product/usa/pi\\_circulars/k/keytruda/keytruda\\_pi.pdf](https://www.merck.com/product/usa/pi_circulars/k/keytruda/keytruda_pi.pdf)). Konstantinopoulos PA, et al. *J Clin Oncol.* 2019;38(11):1222-1245. Oaknin A, et al. *JAMA Oncol.* 2020;6:1766-1772.

18

# Keynote-158: Pembrolizumab for Non-Colorectal dMMR Recurrent Cancer

Distribution of tumor cohorts included in KEYNOTE-158



- Endometrial
- Prostate
- Anal
- Gastric
- Adrenocortical
- Head and neck squamous cell carcinoma
- Pancreatic
- Breast
- Nasopharyngeal
- Small intestine
- Thyroid
- Retroperitoneal
- Ovarian
- Urothelial
- Testicular
- Brain
- Mesothelioma
- Tonsil
- Sarcoma
- Small-cell lung cancer
- Vaginal
- Neuroendocrine tumor
- Renal
- Vulvar
- Cervical
- Salivary

Antitumor activity for tumor types with greatest enrollment


| Tumor type  | No. | CR, No. | PR, No. | ORR, % (95% CI)     |
|-------------|-----|---------|---------|---------------------|
| Endometrial | 49  | 8       | 20      | 57.1 (42.2 to 71.2) |

| Tumor type  | Median PFS, Months (95% CI) | Median OS, Months (95% CI) | Median DOR, Months (range) |
|-------------|-----------------------------|----------------------------|----------------------------|
| Endometrial | 25.7 (4.9 to NR)            | NR (27.2 to NR)            | NR (2.9 to 27.0+)          |

CR = complete response; PR = partial response; NR = not reached; DOR = duration of response. Marabelle A, et al. *J Clin Oncol.* 2019;38:1-10.

19

# Phase 2 Study of Avelumab in Patients With dMMR and Proficient MMR (pMMR) Recurrent/Persistent EC



| Response                 | Number of patients   |                               |
|--------------------------|----------------------|-------------------------------|
|                          | dMMR cohort (n = 15) | pMMR/non-POLE cohort (n = 16) |
| Best overall response    |                      |                               |
| Complete response        | 1                    | 0                             |
| Partial response         | 3                    | 1                             |
| Stable disease (SD)      | 4                    | 4                             |
| Progressive disease (PD) | 4                    | 9                             |
| Not evaluable            | 3                    | 2                             |
| ORR, % (95% CI)          | 26.7 (7.8 to 55.1)   | 6.25 (0.16 to 30.2)           |
| PFS6                     |                      |                               |
| Yes                      | 6                    | 1                             |
| No                       | 9                    | 15                            |
| PFS6, % (95% CI)         | 40 (16.3 to 66.7)    | 6.25 (0.16 to 30.2)           |

PFS6 = progression-free survival of at least 6 months  
Konstantinopoulos PA, et al. *J Clin Oncol.* 2019;37:2786-2794..

20

# GARNET Study: Single Agent Dostarlimab (anti PD-1 antibody) for Recurrent dMMR EC

## Tumor response by RECIST v1.1

| Characteristic                                       | dMMR EC cohort<br>Number (%) (n = 71) |
|--|---------------------------------------|
| <b>Best overall response</b>                         |                                       |
| Complete response                                    | 9 (12.7)                              |
| Partial response                                     | 21 (29.6)                             |
| Stable disease                                       | 11 (15.5)                             |
| Progressive disease                                  | 27 (38.0)                             |
| Not evaluable  | 3 (4.2)                               |
| <b>Confirmed ORR</b>                                 |                                       |
| Number (%) [95% CI]                                  | 30 (42.3) [30.6-54.6]                 |
| Response ongoing                                     | 25/30 (83.3)                          |
| <b>Disease control rate, number (%) [95% CI]</b>     | 41 (57.7) [45.4-69.4]                 |
| <b>Duration of response, median (95% CI), months</b> | Not reached                           |

FDA-approved in April 2021 under accelerated approval for recurrent mismatch repair deficient EC that has progressed on or following prior treatment with a platinum-containing regimen

dMMR = deficient mismatch mutation repair; ORR = objective response rate; RECIST v1.1 = Response Evaluation Criteria in Solid Tumors version 1.1. Oaknin A, et al. *JAMA Oncol.* 2020;6:1766-1772. ClinicalTrials.gov NCT02715284.

21

# PHAEDRA Study: Phase 2, 2-Cohort Study of Durvalumab in Patients With Advanced/Recurrent EC

## Key eligibility criteria

- Eastern Cooperative Oncology Group (ECOG): 0-2
- Advanced/recurrent endometrial cancer with not amenable to curative therapy
- Measurable disease by RECIST v1.1
- Known MMR status tumor tissue by IHC

## Main demographics and disease characteristics


- N=35 pMMR cohort (1-3 prior lines of therapy [LOT])
  - ✓ 31% serous histology; 72% Grade 3
- N=36 dMMR cohort (0-3 prior LOT)
  - ✓ 94% endometrioid histology; 47% Grade 2

Treatment: durvalumab 1500 mg once every 4 weeks (Q4W) until disease progression

## Primary endpoint

- ORR by iRECIST

| Response   | dMMR cohort (n=36) | pMMR cohort (n=35) |
|------------|--------------------|--------------------|
| ORR, n (%) | 17 (47%)           | 1 (3%)             |
| DCR, n (%) | 21 (58%)           | 8 (23%)            |



DCR = disease control rate; OTRR = objective tumor response rate. Antill Y, et al. *J Immunother Cancer.* 2021;9:e002255.


22



## Managing Immune-Related Adverse Events (AEs)

- Immune checkpoint blockade can result in inflammation of any organ
- Patient selection
- Treatment settings
- Clinical trial access
- Team education and communication
- Patient education and expectation setting
- Multidisciplinary care


### Organs affected by checkpoint blockade



Postow MA, et al. *N Engl J Med.* 2018;378:158-168. Menderes G, et al. *Expert Opin Biol.* 2016;16:989-1004. Minion LE, Tewari KS. *Gynecol Oncol.* 2018;148:609-621.

23

## Managing Immune-Related AEs (cont)




- Most immune-related AEs (irAEs) occur within first 6 months of treatment.
- Maintain high level of suspicion that new symptoms are treatment related.
- Use multidisciplinary care.

Weber JS, et al. *J Clin Oncol.* 2015;33:2092-2099. Schneider BJ, et al. *J Clin Oncol.* 2021;39:4073-4126.

24

## Cases and Fatality Rates for Immune-Related AEs



### General recommendations

- *Grade 1*: continue therapy with close monitoring, except for some neurologic, hematologic and cardiac toxicities.
- *Grade 2*: consider holding therapy and resume when symptoms revert to  $\leq$  grade 1. Corticosteroids may be administered.
- *Grade 3*: Hold therapy and initiate high-dose corticosteroids. Taper steroids over at least 4-6 weeks. If no improvement after 48-72 hours, infliximab may be an option for some toxicities.
- *Grade 4*: Permanently discontinue therapy, except for controlled endocrinopathies.

Wang DY, et al. *JAMA Oncol.* 2018;4:1721-1728. Schneider BJ, et al. *J Clin Oncol.* 2021;39:4073-4126.

25

## Single Agent IO Efficacy Is Low in pMMR EC


| Study                                | Drug          | N   | Patient selection                          | ORR (%) |
|--------------------------------------|---------------|-----|--|---------|
| KEYNOTE-28 <sup>1</sup>              | Pembrolizumab | 24  | Advanced/metastatic PD-L1+                 | 13%     |
| Garnet <sup>2</sup>                  | Dostarlimab   | 142 | Previously treated recurrent/advanced pMMR | 13.4%   |
| PHAEDRA <sup>3</sup>                 | Durvalumab    | 36  | Advanced/metastatic pMMR                   | 3%      |
| Konstantinopoulos et al <sup>4</sup> | Avelumab      | 16  | Advanced/metastatic pMMR                   | 6%      |

PD-L1+ = programmed cell-death ligand 1 positive.

1. Ott PA, et al. *J Clin Oncol.* 2017;35(22):2535-2541. 2. Oaknin A, et al. *JAMA Oncol.* 2020;6:1766-1772. 3. Antill Y, et al. *J Immunother Cancer.* 2021;9:e002255. 4. Konstantinopoulos PA, et al. *J Clin Oncol.* 2019;37(30):2786-2794.

26

## KEYNOTE-775 Study Design



BICR = blinded independent central review; ECOG PS = Eastern Cooperative Oncology Group performance status; HRQoL = health-related quality of life; IV = intravenous; PFS = progression-free survival; pMMR = mismatch repair-proficient; ORR = objective response rate; PO = per os (by mouth); QD = once daily, Q3W = every 3 weeks; QW = once weekly. Makker V, et al. *N Engl J Med.* 2022;Epub ahead of print. Makker V, et al. SGO 2021; Abstract 0008/#785.

27

## KEYNOTE-775: Baseline Characteristics


|   | LEN + pembro (n = 411)  | TPC (n = 416)           |
|---|-------------------------|-------------------------|
| Median age (range), years                                 | 64 (30-82)              | 65 (35-86)              |
| MMR status: pMMR/dMMR, %                                  | 84.2 / 15.8             | 84.4 / 15.6             |
| Prior history of pelvic radiation, %                      | 40.9                    | 41.6                    |
| ECOG 0/1, %   | 59.9 / 39.9             | 57.9 / 42.1             |
| Race: White/Black/Asian/other, %                          | 63.5 / 4.1 / 20.7 / 2.9 | 59.1 / 3.4 / 22.1 / 4.8 |
| Histology at diagnosis, %                                 |                         |                         |
| Endometrioid carcinoma high-grade/low-grade/not specified | 22.9 / 14.4 / 21.9      | 21.6 / 13.0 / 26.4      |
| Serous carcinoma  | 25.1                    | 27.6                    |
| Clear cell carcinoma                                      | 7.3                     | 4.1                     |
| Mixed   | 5.4                     | 3.8                     |
| Prior lines of systemic treatment: 1 / ≥2, %              | 72.3 / 27.7             | 66.6 / 33.4             |
| Prior lines of platinum-based treatment: 1 / 2, %         | 79.3 / 20.2             | 75.7 / 24.3             |
| Prior neoadjuvant and/or adjuvant treatment, %            | 54.5                    | 60.3                    |

LEN = Lenvatinib; pembro = pembrolizumab; TPC = treatment of physician's choice. Makker V, et al. *N Engl J Med.* 2022;Epub ahead of print. Makker V, et al. SGO 2021; Abstract 0008/#785.

28

# KEYNOTE-775: Progression-Free Survival

Top-line results: Coprimary endpoints of PFS and OS were met and in favor of the pembrolizumab/lenvatinib arm.




Makker V, et al. *N Engl J Med.* 2022;Epub ahead of print. Makker V, et al. SGO 2021; Abstract 0008/#785.

29

# KEYNOTE-775: Overall Survival

Top-line results: Coprimary endpoints of PFS and OS were met and in favor of the pembrolizumab/lenvatinib arm.



Makker V, et al. *N Engl J Med.* 2022;Epub ahead of print. Makker V, et al. SGO 2021; Abstract 0008/#785.

30

## KEYNOTE-775: Additional Results

|   | pMMR             |                  | All-comers       |                  |
|---|------------------|------------------|------------------|------------------|
|   | LEN + pembro     | TPC              | LEN + pembro     | TPC              |
| Patients, n                                 | 346              | 351              | 411              | 416              |
| Objective response rate, % (95% CI)         | 30.3 (25.5-35.5) | 15.1 (11.5-19.3) | 31.9 (27.4-36.6) | 14.7 (11.4-18.4) |
| Difference vs TPC, %                        | 15.2             | –                | 17.2             | –                |
| P-value                                     | < 0.0001         | –                | < 0.0001         | –                |
| Best overall response, %                    |                  |                  |                  |                  |
| Complete response                           | 5.2              | 2.6              | 6.6              | 2.6              |
| Partial response                            | 25.1             | 12.5             | 25.3             | 12.0             |
| Stable disease                              | 48.6             | 39.6             | 47.0             | 40.1             |
| Progressive disease                         | 15.6             | 30.8             | 14.8             | 29.6             |
| Not evaluable/assessed                      | 0.6 / 4.9        | 2.0 / 12.5       | 1.2 / 5.1        | 1.9 / 13.7       |
| Median duration of response (range), months | 9.2 (1.6-23.7)   | 5.7 (0.0-24.2)   | 14.4 (1.6-23.7)  | 5.7 (0.0-24.2)   |
| Median time to response (range), months     | 2.1 (1.5-9.4)    | 3.5 (1.0-7.4)    | 2.1 (1.5-16.3)   | 2.1 (1.0-7.4)    |

Makker V, et al. *N Engl J Med.* 2022;Epub ahead of print. Makker V, et al. SGO 2021; Abstract 0008/#785.

31

## KEYNOTE-775: TEAEs With Frequency $\geq 25\%$ in All-Comers

|                             | LEN + pembro<br>(n = 406) |                  | TPC<br>(n = 388) |                  |
|-----------------------------|---------------------------|------------------|------------------|------------------|
|                             | Any Grade                 | Grade $\geq 3^a$ | Any Grade        | Grade $\geq 3^a$ |
| Patients with any TEAEs, %  | 99.8                      | 88.9             | 99.5             | 72.7             |
| Hypertension                | 64.0                      | 37.9             | 5.2              | 2.3              |
| Hypothyroidism <sup>b</sup> | 57.4                      | 1.2              | 0.8              | 0.0              |
| Diarrhea                    | 54.2                      | 7.6              | 20.1             | 2.1              |
| Nausea                      | 49.5                      | 3.4              | 46.1             | 1.3              |
| Decreased appetite          | 44.8                      | 7.9              | 21.1             | 0.5              |
| Vomiting                    | 36.7                      | 2.7              | 20.9             | 2.3              |
| Weight decrease             | 34.0                      | 10.3             | 5.7              | 0.3              |
| Fatigue                     | 33.0                      | 5.2              | 27.6             | 3.1              |
| Arthralgia                  | 30.5                      | 1.7              | 8.0              | 0.0              |
| Proteinuria                 | 28.8                      | 5.4              | 2.8              | 0.3              |
| Anemia                      | 26.1                      | 6.2              | 48.7             | 14.7             |
| Constipation                | 25.9                      | 0.7              | 24.7             | 0.5              |
| Urinary tract infection     | 25.6                      | 3.9              | 10.1             | 1.0              |
| Headache                    | 24.9                      | 0.5              | 8.8              | 0.3              |
| Asthenia                    | 23.6                      | 5.9              | 24.5             | 3.9              |
| Neutropenia                 | 7.4                       | 1.7              | 33.8             | 25.8             |
| Alopecia                    | 5.4                       | 0.0              | 30.9             | 0.5              |

<sup>a</sup>In the LEN + pembro arm, 5.7% of patients died due to grade 5 events (gastrointestinal disorders: 1.2%, cardiac disorders: 0.5%, general disorders: 1.5%, infections: 0.7%, decreased appetite: 0.2%, neoplasms, nervous system, psychiatric, renal, reproductive, or respiratory disorders: 0.2% each). In the TPC arm, 4.9% of patients died due to grade 5 events (cardiac disorders: 1%, general disorders: 1.3%, infections: 1.5%, subdural hematoma: 0.3%, respiratory disorders: 0.8%). <sup>b</sup>Adverse event of interest for pembrolizumab.

Makker V, et al. *N Engl J Med.* 2022;Epub ahead of print. Makker V, et al. SGO 2021; Abstract 0008/#785.

32

## KEYNOTE-775: Treatment Exposure, Safety, and Discontinuation in All-Comers

|   | LEN + pembro (n = 406) | TPC (n = 388) |
|---|------------------------|---------------|
| Median duration of treatment (range), days                  | 231 (1-817)            | 104.5 (1-785) |
| Patients with any TEAEs, %                                  | 99.8                   | 99.5          |
| Grade ≥3  | 88.9                   | 72.7          |
| Patients with any TEAEs leading to dose reductions, %       | 66.5                   | 12.9          |
| Patients with any-grade TEAEs leading to interruption, %    | 69.2                   | 27.1          |
| LEN   | 58.6                   | –             |
| Pembro  | 50.0                   | –             |
| LEN + pembro  | 30.8                   | –             |
| Patients with any-grade TEAEs leading to discontinuation, % | 33.0                   | 8.0           |
| LEN   | 30.8                   | –             |
| Pembro  | 18.7                   | –             |
| LEN + pembro  | 14.0                   | –             |

Median dose intensity of lenvatinib was 13.8 mg per day

Makker V, et al. *N Engl J Med.* 2022;Epub ahead of print. Makker V, et al. SGO 2021; Abstract 0008/#785.


33

## Emerging Therapies

34

## Targeting WEE1 in Uterine Serous or p53-Mutated Uterine Cancers


- Uterine serous cancer (USC)/serous-like cancers are a subtype of EC with aggressive features, accounting for up to 40% of uterine cancer mortality
- Beyond carboplatin/paclitaxel and pembrolizumab/lenvatinib, there is limited activity of standard therapies in USC
- Molecular characterization of USC demonstrates multiple molecular characteristics suggestive of **high replication stress**
  - CCNE1 amplification, MYC amplification, KRAS mutation, RB1 loss, ERBB2 amplification



35

## p53 Mutation and WEE1 Inhibition



- WEE1 regulates the G2/M checkpoint: the Gatekeeper
- Cells with p53 aberrant expression/mutation or loss lose G1/S checkpoint
- Increases replication stress
- Increases dependence on G2/M checkpoint
- Synthetic lethality



Liu JF, et al. *J Clin Oncol*. 2021;39(14):1531-1539.

36

## WEE1 Inhibition: Adavosertib in Uterine Serous Carcinoma



- 29.4% ORR
- 38.2% Clinical benefit response (CBR)
- DOR: 6.2 months
- PFS6: 55.6%

### Open studies:



NCT04590248: Phase 2 of adavosertib in recurrent endometrial serous cancer  
 NCT04814108: Phase 2 of ZN-c3 in recurrent endometrial serous cancer

Liu et al. *J Clin Oncol.* 2021;39(14):1531-1539.

37

## CDK4/6 Inhibitors

- Phase 2 trial of ribociclib and letrozole in patients with relapsed estrogen receptor-positive ovarian or endometrial cancers
- 20 patients with EC enrolled; PFS12 was primary endpoint
- 2 confirmed responses in EC



Cohort A is the ovarian cancer cohort, and cohort B is the endometrial cancer cohort.  
 Other phase 2 studies testing abemaciclib: NCT03675893 (DFCI), NCT04393285 (GOG)

NCT02657928

Colon-Otero G, et al. *ESMO Open.* 2020;5:e000926.

38



# PALEO Study (ESMO 2020)


## ENGOT-EN3/NDGO-PALEO trial design

### Key inclusion criteria

- Measurable/evaluable endometrial cancer
- Primary Stage 4 or relapsed disease
- ≥1 prior systemic therapy
- ER+ (≥10%) endometrioid adenocarcinoma
- ECOG PS 0/1
- No prior endocrine therapy except MPA and megestrol acetate
- No prior CDK inhibitor

### Stratification

- Number of prior lines (primary advanced disease vs 1st relapse vs ≥2 relapses)
- Measurable vs evaluable disease per RECIST
- Prior use of MPA/megestrol acetate



**Primary endpoint:** Investigator-assessed PFS (target HR 0.625, 80% power, 15% 1-sided  $\alpha$ )

**Secondary endpoints**

- PFS in subgroups
- Objective response rate, disease control rate, PFS2, overall survival
- PROs

## Baseline characteristics


| Characteristics, n (%)             |            | Palbociclib + Letrozole (n=35) | Placebo + Letrozole (n=37) |
|------------------------------------|------------|--------------------------------|----------------------------|
| Median age, years (range)          |            | 68.5 (36-82)                   | 67 (29-83)                 |
| Previous cancer                    |            | 3 (8)                          | 4 (11)                     |
| Diabetes                           |            | 6 (17)                         | 3 (8)                      |
| Hypertension                       |            | 17 (47)                        | 13 (35)                    |
| Other comorbidities                |            | 3 (8)                          | 4 (11)                     |
| RECIST status                      | Measurable | 32 (89)                        | 31 (84)                    |
|                                    | Evaluable  | 4 (11)                         | 6 (16)                     |
| Prior use of megestrol acetate/MPA |            | 4 (11)                         | 7 (19)                     |
| Prior lines of therapy             | 0          | 5 (14)                         | 4 (11)                     |
|                                    | 1          | 19 (53)                        | 17 (46)                    |
|                                    | ≥2         | 12 (33)                        | 16 (43)                    |

HR = hazard ratio; MPA = medroxyprogesterone acetate; CDK = cyclin-dependent kinase; PROs = patient-reported outcomes.  
Mirza MR, et al. European Society of Medical Oncology (ESMO) 2020; Abstract LBA28.

39


# PALEO Results

## Efficacy (intention-to-treat population)




No. at risk

|           |    |    |    |
|-----------|----|----|----|
| PAL + LET | 36 | 21 | 14 |
| PBO + LET | 37 | 17 | 10 |




## PFS by stratification factors



No. at risk

|           |    |    |    |
|-----------|----|----|----|
| PAL + LET | 32 | 20 | 14 |
| PBO + LET | 30 | 15 | 9  |



No. at risk

|           |    |    |    |
|-----------|----|----|----|
| PAL + LET | 31 | 17 | 10 |
| PBO + LET | 33 | 15 | 8  |

CI = confidence interval; HR = hazard ratio; PAL = palbociclib; LET = letrozole.


\*At 24 weeks.

Mirza MR, et al, ESMO 2020; Abstract LBA28.

40

## PALEO Toxicities: Summary of Adverse Events

Any grade in  $\geq 20\%$  of patients and/or  $>1$  patient with Grade  $\geq 3$  in either arm




Mirza MR, et al. ESMO 2020; Abstract LBA28.

41

## Other Targeted Therapies: ATR Inhibitors

- Phase 2 study of the ATR inhibitor ceralasertib, alone and in combination with olaparib, in patients with ARID1A-deficient and ARID1A-intact solid tumors
- Rationale: Loss of ARID1A leads to increased reliance on ATR kinase
- 2 cohorts enrolled: ARID1A deficient (cohort 1, ceralasertib monotherapy) and ARID1A intact (cohort 2, ceralasertib combined with olaparib)
- In cohort 1, the ORR was 20% with 2 complete responses (CRs) observed; both patients were patients with EC who remained on treatment for 21.3+ and 16.3+ months, respectively. No responses in cohort 2




ATARI trial: Ceralasertib inhibitor in combination with olaparib in gynecological cancers with ARID1A loss or no loss (ENGOT/GYN1/NCRI) (NCT04065269): currently open

SLD = sum of the longest diameters. ESMO 2021 (<https://www.esmo.org/oncology-news/antitumour-activity-of-ceralasertib-in-arid1a-deficient-solid-tumours>).

42

# Managing Endometrial Cancer Requires a Multidisciplinary Approach



- Improved outcomes
- Early identification of irAEs
- Better QoL
- Provides individualized care
- Optimized treatment
- Management of comorbidities
- Enables shared decision-making

43

## Case Study

53-year-old woman

44

## Case Study: 53-Year-Old Female

- In 2019, patient presented with postmenopausal bleeding. Endometrial biopsy was consistent with low-grade endometrioid endometrial cancer with a few poorly differentiated foci.
- She underwent total laparoscopic hysterectomy, bilateral salpingo-oophorectomy (BSO), omentectomy, resection of perirectal tumor, and resection of peritoneal nodules; complete surgical resection
- Pathology consistent with endometrioid adenocarcinoma, poorly differentiated, invading less than 5% of the myometrial thickness. Areas of gross metastases: left ovary and omentum; ER and PR negative

45

## Treatment and Testing

- **Patient received carboplatin and paclitaxel x 6 cycles**
- **6 months later, surveillance CT showed** development of metastatic recurrence with small liver and peritoneal lesions, and left axillary and subpectoral lymph nodes, consistent with relapsed cancer

### Next generation sequencing (NGS) results:

Tumor mutational burden (TMB)/megabase: 6.083

MMR status: Proficient

Mutations: PIK3CA c.1624G>A (p.E542K)

No other targetable mutations

CT = computerized tomography.

46

*How would you manage this patient?*


47

## Second-line Treatment


- Lenvatinib 20 mg by mouth and pembrolizumab 200 mg IV started in November 2020
- CT scan after 3 cycles of pembrolizumab/lenvatinib showed progression

CT in January 2021 showed progression of liver metastases and peritoneal disease.

October 2020



January 2021



48

*How would you manage this patient?*

49

## Further Treatment

Started carboplatin AUC 5 and weekly paclitaxel 80 mg/m<sup>2</sup> x 10 cycles



January 2021  
at start of treatment



After 3 cycles  
of carboplatin/paclitaxel



At completion  
of carboplatin/paclitaxel



3 months after  
completion of  
carboplatin/  
paclitaxel

50

## Case Study

62-year-old woman

51

### Case: 62-Year-Old White Female

- 2010: Vaginal spotting; endometrial biopsy showed a Grade I EC
- Staging surgery showed an endometrial adenocarcinoma, endometrioid mucinous type, Grade I. MMR testing: *MSH2*, *MSH6* (normal); *MLH1*, *PMS2* (abnormal)
- Stage IA Grade 1 endometrioid endometrial cancer; the cancer was minimally invasive of the myometrium. No further treatment recommended
- 1 year later she self-palpated a right inguinal lymph node. Positron emission tomography (PET) showed lymphadenopathy in the right pelvis and inguinal regions with no other sites of cancer in the upper abdomen. Biopsy was positive for malignant cells
- She started carboplatin/paclitaxel, then followed by involved field radiotherapy and 3 additional courses of carboplatin/paclitaxel; megestrol started as maintenance
- She was followed by every 6 months with CT scans
- 3 years later, there was documented recurrent cancer with enlarged RTP nodes and pelvic side wall disease

52

*How would you manage this patient?*

53

### **Case: 62-Year-Old White Female (continued)**

- Patient was started on pembrolizumab in 2018, and after 5 months of treatment (7 doses) she was hospitalized for severe watery diarrhea. At that time flexible sigmoidoscopy with biopsy showed no colitis. She was treated with steroids and had rapid improvement. Pembrolizumab was held during steroid treatment and tapered
- 2 months later after resolution of diarrhea and completion of steroid course, she was rechallenged with pembrolizumab, and again developed severe watery diarrhea.

*How would you manage this adverse event?*

54



## Case 6: 62-Year-Old White Female (continued)

- Patient was again hospitalized for severe diarrhea
- She was started on 1 mg/kg methylprednisolone, which was increased to 2 mg/kg because of lack of improvement
- Colon biopsy was positive for checkpoint inhibitor induced colitis. She was unable to taper below 50 mg of prednisone and received 3 doses of infliximab over the next 3 months.
- No further pembrolizumab given. Diarrhea eventually completely resolved and steroids stopped
- CT scans x 3 years have shown no evidence of disease

55

**Thank You**

**Q & A**

56

**Immuno-Oncology Therapies for the Treatment of Advanced Endometrial Cancer:  
Which of Your Patients May Benefit from Their Use?**

| Resource   | Address  |
|--|--|
| <p>Henley SJ, Miller JW, Dowling NF, Benard VB, Richardson LC. <b>Uterine cancer incidence and mortality - United States, 1999-2016.</b> <i>MMWR Morb Mortal Wkly Rep.</i> 2018;67:1333-1338.</p>  | <p><a href="https://pubmed.ncbi.nlm.nih.gov/30521505/">https://pubmed.ncbi.nlm.nih.gov/30521505/</a></p> |
| <p>The Cancer Genome Atlas Research Network, Kandoth C, Schultz N, et al. <b>Integrated genomic characterization of endometrial carcinoma.</b> <i>Nature.</i> 2013;497:67-73.</p>  | <p><a href="https://pubmed.ncbi.nlm.nih.gov/23636398/">https://pubmed.ncbi.nlm.nih.gov/23636398/</a></p> |
| <p>Miller DS, Filiaci VL, Mannel RS, et al. <b>Carboplatin and paclitaxel for advanced endometrial cancer: Final overall survival and adverse event analysis of a phase III trial (NRG Oncology/GOG0209).</b> <i>J Clin Oncol.</i> 2020;38:3841-3850.</p>  | <p><a href="https://pubmed.ncbi.nlm.nih.gov/33078978/">https://pubmed.ncbi.nlm.nih.gov/33078978/</a></p> |
| <p>Fader AN, Roque DM, Siegel E, et al. <b>Randomized phase II trial of carboplatin-paclitaxel compared with carboplatin-paclitaxel-trastuzumab in advanced (stage III-IV) or recurrent uterine serous carcinomas that overexpress Her2/Neu (NCT01367002): Updated overall survival analysis.</b> <i>Clin Cancer Res.</i> 2020;26:3928-3935.</p> | <p><a href="https://pubmed.ncbi.nlm.nih.gov/32601075/">https://pubmed.ncbi.nlm.nih.gov/32601075/</a></p> |
| <p>MacKay HJ, Levine DA, Bae-Jump VL, et al. <b>Moving forward with actionable therapeutic targets and opportunities in endometrial cancer: NCI clinical trials planning meeting report on identifying key genes and molecular pathways for targeted endometrial cancer trials.</b> <i>Oncotarget.</i> 2017;8:84579-84594.</p>                   | <p><a href="https://pubmed.ncbi.nlm.nih.gov/29137450/">https://pubmed.ncbi.nlm.nih.gov/29137450/</a></p> |
| <p>Luchini C, Bibeau F, Ligtenberg MJL, et al. <b>ESMO recommendations on microsatellite instability testing for immunotherapy in cancer, and its relationship with PD-1/PD-L1 expression and tumour mutational burden: A systematic review-based approach.</b> <i>Ann Oncol.</i> 2019;30:1232-1243.</p>   | <p><a href="https://pubmed.ncbi.nlm.nih.gov/31056702/">https://pubmed.ncbi.nlm.nih.gov/31056702/</a></p> |
| <p>Ott PA, Bang YJ, Berton-Rigaud D, et al. <b>Safety and antitumor activity of pembrolizumab in advanced programmed death ligand 1-positive endometrial cancer: Results from the KEYNOTE-028 study.</b> <i>J Clin Oncol.</i> 2017;35:2535-2541.</p>   | <p><a href="https://pubmed.ncbi.nlm.nih.gov/28489510/">https://pubmed.ncbi.nlm.nih.gov/28489510/</a></p> |

|  |  |
|--|--|
| <p>Marabelle A, Le DT, Ascierto PA, et al. <b>Efficacy of pembrolizumab in patients with noncolorectal high microsatellite instability/mismatch repair-deficient cancer: Results from the phase II KEYNOTE-158 study.</b> <i>J Clin Oncol.</i> 2019;38:1-10.</p>   | <p><a href="https://pubmed.ncbi.nlm.nih.gov/31682550/">https://pubmed.ncbi.nlm.nih.gov/31682550/</a></p>       |
| <p>Oaknin A, Tinker AV, Gilbert L, et al. <b>Clinical activity and safety of the anti-programmed death 1 monoclonal antibody dostarlimab for patients with recurrent or advanced mismatch repair-deficient endometrial cancer: A nonrandomized phase 1 clinical trial.</b> <i>JAMA Oncol.</i> 2020;6:1766-1772.</p>  | <p><a href="https://pubmed.ncbi.nlm.nih.gov/33001143/">https://pubmed.ncbi.nlm.nih.gov/33001143/</a></p>       |
| <p>Konstantinopoulos PA, Luo W, Liu JF, et al. <b>Phase II study of avelumab in patients with mismatch repair deficient and mismatch repair proficient recurrent/persistent endometrial cancer.</b> <i>J Clin Oncol.</i> 2019;37:2786-2794.</p>  | <p><a href="https://pubmed.ncbi.nlm.nih.gov/31461377/">https://pubmed.ncbi.nlm.nih.gov/31461377/</a></p>       |
| <p>Wang D, Lin J, Yang X, et al. <b>Combination regimens with PD-1/PD-L1 immune checkpoint inhibitors for gastrointestinal malignancies.</b> <i>J Hematol Oncol.</i> 2019;12:42.</p>   | <p><a href="https://pubmed.ncbi.nlm.nih.gov/31014381/">https://pubmed.ncbi.nlm.nih.gov/31014381/</a></p>       |
| <p>Makker V, Rasco D, Vogelzang NJ, et al. <b>Lenvatinib plus pembrolizumab in patients with advanced endometrial cancer: An interim analysis of a multicentre, open-label, single-arm, phase 2 trial.</b> <i>Lancet Oncol.</i> 2019;20:711-718.</p>   | <p><a href="https://pubmed.ncbi.nlm.nih.gov/30922731/">https://pubmed.ncbi.nlm.nih.gov/30922731/</a></p>       |
| <p>Makker V, et al. <b>Lenvatinib plus pembrolizumab in patients with advanced endometrial cancer.</b> <i>J Clin Oncol.</i> 2020;38:2981-2992.</p>   | <p><a href="https://pubmed.ncbi.nlm.nih.gov/32167863/">https://pubmed.ncbi.nlm.nih.gov/32167863/</a></p>       |
| <p>Makker V, Colombo N, Casado Herráez A, et al. <b>O008/#785 A multicenter, open-label, randomized phase 3 study to compare the efficacy and safety of lenvatinib in combination with pembrolizumab vs treatment of physician's choice in patients with advanced endometrial cancer: Study 309/KEYNOTE-775.</b> <i>Int J Gynecol Cancer.</i> 2021;31:A4-A5.</p> | <p><a href="https://ijgc.bmj.com/content/31/Suppl_4/A4.2">https://ijgc.bmj.com/content/31/Suppl_4/A4.2</a></p> |
| <p>Schneider BJ, Naidoo J, Santomaso BD, et al. <b>Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: ASCO guideline update.</b> <i>J Clin Oncol.</i> 2021;39:4073-4126.</p>  | <p><a href="https://pubmed.ncbi.nlm.nih.gov/34724392/">https://pubmed.ncbi.nlm.nih.gov/34724392/</a></p>       |
| <p>Postow MA, Sidlow R, Hellmann MD. <b>Immune-related adverse events associated with immune checkpoint blockade.</b> <i>N Engl J Med.</i> 2018;378:158-168.</p>   | <p><a href="https://pubmed.ncbi.nlm.nih.gov/29320654/">https://pubmed.ncbi.nlm.nih.gov/29320654/</a></p>       |

|   |  |
|---|--|
| <p>Weber JS, Yang JC, Atkins MB, Disis ML. <b>Toxicities of immunotherapy for the practitioner.</b> <i>J Clin Oncol.</i> 2015;33:2092-2099.</p>   | <p><a href="https://pubmed.ncbi.nlm.nih.gov/25918278/">https://pubmed.ncbi.nlm.nih.gov/25918278/</a></p> |
| <p>Wang DY, Salem JE, Cohen JV, et al. <b>Fatal toxic effects associated with immune checkpoint inhibitors: A systematic review and meta-analysis.</b> <i>JAMA Oncol.</i> 2018;4:1721-1728.</p> | <p><a href="https://pubmed.ncbi.nlm.nih.gov/30242316/">https://pubmed.ncbi.nlm.nih.gov/30242316/</a></p> |